Back to Stakeholders

Federal Agencies Grant-Making Organizations

VA Office of Research and Development

United States

9 Trials

The research and development arm of the U.S. Department of Veterans Affairs, funding and conducting clinical trials to advance veteran health. Has allocated significant resources to studying MDMA- and psilocybin-assisted therapies for PTSD and other mental health conditions affecting veterans.

Quick Facts

Type: Other
HQ: United States
Website: Visit

Sponsored Trials

8

Not yet recruitingIII

Psilocybin Intervention for Veterans Overcoming Treatment-Resistant Depression

Start Date: June 1, 2026
Compounds: Psilocybin

Ketamine-assisted Integrative Treatment for Veterans With Chronic Low Back Pain and Comorbid Depression

Start Date: December 1, 2024
Compounds: Ketamine

Ketamine for Veterans With Parkinson’s Disease (KPD)

Start Date: July 1, 2024
Compounds: Ketamine, Placebo

VA Aripiprazole vs Esketamine for Treatment Resistant Depression (VAST-D II)

Start Date: October 27, 2023
Compounds: Esketamine

Ketamine-enhanced Prolonged Exposure Therapy in PTSD

Start Date: March 9, 2021
Compounds: Ketamine, Placebo

Ketamine for Treatment Resistant Late-Life Depression

Start Date: October 1, 2015
Compounds: Ketamine, Placebo

Efficacy of Repeated Ketamine Infusions for Treatment-resistant Depression

Start Date: April 1, 2015
Compounds: Ketamine, Placebo

Ketamine for the Rapid Treatment of Major Depressive Disorder and Alcohol Use Disorder

Start Date: January 1, 2015
Compounds: Ketamine, Placebo

Collaborated Trials

1

Imaging SV2A in Mood Disorders

Start Date: April 1, 2016
Compounds: Ketamine